The individualized management for neoadjuvant therapy  of  breast  cancer        DUAN Xue-ning,  ZHANG Chi,  XU Ling.  Department of Surgery, Peking University First Hospital, Beijing 100034, China
Corresponding author：DUAN Xue-ning，E-mail：xuening666@126.com
Abstract   As one of the standardized treatments, neoadjuvant treatment for breast cancer has been paid more and more attention.  At the same time, discussion on the advantage and shortage of neoadjuvant treatment compared with adjuvant treatment exists constantly. However, the fact that the patients who achieved pCR from neoadjuvant treatment had a much better prognosis reveals a promising perspective. It also urges surgeons to study on the available biomarker to predict pCR and the most effective schedule to achieve pCR. In addition, some approaches such as MR, CTCs and so on are important in monitoring disease and predicting responsive rate, by which neoadjuvant treatment could be carried out under control and safely. More important is that the patients could be treated personally and be benefited mostly.